Huidagene Therapeutics key facts
- Developer of gene therapy drugs designed for the treatments of rare human genetic diseases.
- It has raised $80.4M; the latest was Later Stage VC in Mar 2026.
- Notable investors include GL Ventures, Beijing Ruiyin Weiye Technology Development, HM Capital, HM Venture Partners, Kunnuo Tianqin Venture Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·Watch Huidagene Therapeutics: the Monday email on marks, rounds and moves
Huidagene Therapeutics funding rounds
No funding rounds for Huidagene Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Huidagene Therapeutics investors
7 investors are on record for Huidagene Therapeutics, including GL Ventures, Beijing Ruiyin Weiye Technology Development, HM Capital and HM Venture Partners.
About Huidagene Therapeutics
Developer of gene therapy drugs designed for the treatments of rare human genetic diseases. The company specializes in the development and production of gene replacement and gene editing therapeutic products based on Adeno-Associated Virus technologies, providing sophisticated and reliable research and solutions for the treatment of various neurodegenerative diseases.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Employees
- 150
- Website
- cn.huidagene.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Huidagene Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.